reports
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jean-François Granjon
- Louis Boujard
- CFA
- Thomas Zlowodzki
CGM CEGEDIM SA
VETO VETOQUINOL SA
KOF KAUFMAN & BROAD SA
ALLAN LANSON-BCC
ALCAR CARMAT SA
BAMNB KONINKLIJKE BAM GROEP NV
ELIS ELIS SA
GNFT GENFIT SA
SEFER SERGEFERRARI GROUP SA
SSO SCATEC ASA
RBO ROCHE BOBOIS INTERNATIONAL SAS
WAVE WAVESTONE SA
SFQ SAF-HOLLAND SE
ALHRS HYDROGEN REFUELING SOLUTIONS
LHYFE LHYFE S.A.
- Andreas Riemann
- Jean Danjou
- Thomas Zlowodzki
CGM CEGEDIM SA
VETO VETOQUINOL SA
KOF KAUFMAN & BROAD SA
ALLAN LANSON-BCC
ALCAR CARMAT SA
BAMNB KONINKLIJKE BAM GROEP NV
ELIS ELIS SA
GNFT GENFIT SA
SEFER SERGEFERRARI GROUP SA
SSO SCATEC ASA
RBO ROCHE BOBOIS INTERNATIONAL SAS
WAVE WAVESTONE SA
SFQ SAF-HOLLAND SE
ALHRS HYDROGEN REFUELING SOLUTIONS
MRX MISTER SPEX SE
LHYFE LHYFE S.A.
- Jean-François Granjon
- Jean-François Granjon
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Emmanuel Matot
- Marc Lavaud
- Emmanuel Matot
- Marc Lavaud
- Martial Descoutures
- Oussema Denguir
Valbiotis : TOTUM-854 lowers blood pressure
>Positive results from the Insight trial - Valbiotis announced after the market close yesterday positive results for TOTUM-854 in the control of mild hypertension. The primary endpoint of the trial was achieved, with a significant difference vs placebo in lowering systolic blood pressure (SBP) in individuals with mild untreated hypertension (p
- Martial Descoutures
- Oussema Denguir
Valbiotis : TOTUM-854 baisse la pression artérielle
>Résultats positifs de l’essai Insight - Valbiotis annonçait hier après marché les résultats positifs de TOTUM-854 dans le control de l’hypertension artérielle légère. Le critère principal de l’étude est atteint, avec une différence significative vs placebo sur la diminution de la pression artérielle systolique (PAS) chez des individus présentant une hypertension légère non traitée (p
- Luis de Toledo Heras
ODDO BHF Small & MIDCAP MORNING NEWS - 10/10/2024
Burckhardt Compression is a leading global supplier of compression solutions with a unique product offering (full range of reciprocating compressor technologies and services). It targets profitable growth with a 2022-2027e sales CAGR of 7.7% and a 2022-2027e EBIT CAGR of 12.1%. These prospects seem adequately discounted at our TP of CHF 612 reflecting historical and peer multiples. We initiate the coverage with a Neutral rating. - ...
- Jean-François Granjon
HRS : Confirmation of the previous guidance
>Full-year results publication in line (year to end-June) - Based on full-year sales (already published) of € 24.7m (cf. our first take of 26 July 2024) down 17.6%, HRS has published full-year results in line with our forecasts. The group therefore reported an underlying EBITDA loss of -€ 8.7m (-€ 8.4m estimated and -€ 8.3m for the consensus) vs -€ 2m a year earlier, unsurprisingly reflecting a marked deterioration vs 2023 with a more or less equivalent loss from one ...
- Luis de Toledo Heras
ODDO BHF Small & MIDCAP MORNING NEWS - 10/10/2024
Burckhardt Compression is a leading global supplier of compression solutions with a unique product offering (full range of reciprocating compressor technologies and services). It targets profitable growth with a 2022-2027e sales CAGR of 7.7% and a 2022-2027e EBIT CAGR of 12.1%. These prospects seem adequately discounted at our TP of CHF 612 reflecting historical and peer multiples. We initiate the coverage with a Neutral rating. - ...
- Jean-François Granjon
HRS : Confirmation des guidances précédentes
>Publication des résultats annuels en ligne (clôture le 30 juin) - Sur la base d’un CA annuel déjà publié de 24.7 M€ (cf. notre commentaire du 26 juillet 2024) en repli de 17.6%, HRS publie des résultats en ligne avec nos attentes. L’EBITDA courant ressort ainsi à -8.7 M€ (-8.4 M€ estimé, -8.3m pour le css) vs -2 M€ YoY traduisant sans surprise une nette dégradation vs 2023 avec une perte quasiment équivalente d’un semestre à l’autre. Le ROC ressort pour sa part à -13...
- Jerôme Bodin
PROX PROXIMUS SA DE DROIT PUBLIC
BEKB BEKAERT SA
VCT VICAT-CIMENTS VICAT SA
BFIT BASIC-FIT NV
GTT GAZTRANSPORT & TECHNIGAZ SA
NXI NEXITY SA CLASS A
TFI TELEVISION FRANCAISE 1 SA
BIO BB BIOTECH AG
ALCLA CLASQUIN SA
DEC JCDECAUX SA
ASY ASSYSTEM SA
BLC BASTIDE LE CONFORT MEDICAL SA
ALTR ALTRI SGPS SA
CGM CEGEDIM SA
SRP SRP GROUPE SA
FII LISI SA
LSS LECTRA SA
LNA LNA SANTE SA
GBT GUERBET SA
GOE GROUPE GORGE SA
ATE ALTEN SA
FR VALEO SE
ERA ERAMET SA
COFB COFINIMMO SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
ROYAL VOPAK NV
SESL SES-IMAGOTAG SA
SEFER SERGEFERRARI GROUP SA
WAF SILTRONIC AG
WBD WEBUILD S.P.A.
INSD VERIMATRIX SA
SPIE SPIE SA
TEC TECHNIPFMC PLC
XFAB X-FAB SILICON FOUNDRIES SE
HOME NEINOR HOMES SA
SMCP SMCP SA
BFSA BEFESA SA
VOS VOSSLOH AG
2CRSI 2CRSI SA
NEOEN NEOEN S.A.
HAG HENSOLDT AG
VK VALLOUREC SA
ALHRS HYDROGEN REFUELING SOLUTIONS
FORSE FORSEE POWER SA
SPM SAIPEM S.P.A.
FLOW FLOW TRADERS LTD
AF AIR FRANCE - KLM
- Jerôme Bodin
PROX PROXIMUS SA DE DROIT PUBLIC
BEKB BEKAERT SA
VCT VICAT-CIMENTS VICAT SA
BFIT BASIC-FIT NV
GTT GAZTRANSPORT & TECHNIGAZ SA
NXI NEXITY SA CLASS A
TFI TELEVISION FRANCAISE 1 SA
BIO BB BIOTECH AG
ALCLA CLASQUIN SA
DEC JCDECAUX SA
ASY ASSYSTEM SA
BLC BASTIDE LE CONFORT MEDICAL SA
ALTR ALTRI SGPS SA
CGM CEGEDIM SA
SRP SRP GROUPE SA
FII LISI SA
LSS LECTRA SA
LNA LNA SANTE SA
GBT GUERBET SA
GOE GROUPE GORGE SA
ATE ALTEN SA
FR VALEO SE
ERA ERAMET SA
ELIS ELIS SA
COFB COFINIMMO SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
ROYAL VOPAK NV
SESL SES-IMAGOTAG SA
SEFER SERGEFERRARI GROUP SA
WAF SILTRONIC AG
WBD WEBUILD S.P.A.
INSD VERIMATRIX SA
SPIE SPIE SA
TEC TECHNIPFMC PLC
XFAB X-FAB SILICON FOUNDRIES SE
HOME NEINOR HOMES SA
SMCP SMCP SA
BFSA BEFESA SA
VOS VOSSLOH AG
2CRSI 2CRSI SA
NEOEN NEOEN S.A.
S30 SOLUTIONS 30 SE
HAG HENSOLDT AG
VK VALLOUREC SA
ALHRS HYDROGEN REFUELING SOLUTIONS
FORSE FORSEE POWER SA
SPM SAIPEM S.P.A.
FLOW FLOW TRADERS LTD
AF AIR FRANCE - KLM
- Jean-François Granjon
HRS : Sales below expectations and a disappointing guidance
>FY sales below expectations - HRS has published FY sales (closing on 30 June) of € 24.7m (€ 31.1m est., consensus € 31.3m) vs € 30m YoY, down 17.6%. This revenue is lower than the guidance that had been revised downwards at the beginning of the year, namely € 31m-€ 40m. This is explained by the lower completion of projects as well as the cancellation of certain orders. Station sales came in at € 21.9m vs € 26.5m (-17.5%). Note that H2 sales came in at € 11.9m (-37.7...
- Jean-François Granjon
HRS : Un CA inférieur aux attentes et des guidances décevantes
>CA annuel inférieur aux attentes - HRS publie un CA annuel (clôture le 30 juin) de 24.7 M€ (31.1 M€ estimé, 31.3 M€ pour le consensus) vs 30 M€ YoY en repli de 17.6%. Ce CA est inférieur aux guidances qui avaient été revues en baisse en début d’année à savoir 31/40 M€. Cela s’explique par la moindre réalisation de projets ainsi que par l’annulation de certaines commandes. Le CA station ressort ainsi à 21.9 M€ vs 26.5 M€ (-17.5%). A noter que le CA S2 ressort à 11.9 ...
- Team Pharma
ODDO : The macroeconomic environment is not helping the sector
The last few weeks had seen renewed interest in the sector, with stronger volumes, M&A activity and market transactions. Unfortunately, the political context in France has again undermined French biotechs. A large number of clinical results are expected in the next few months (Ose, Aelis, Genfit, Medincell, Trangsene, Abivax, etc.). If successful, these could reinvigorate the sector. In the meantime, we are taking a more decisive stance, increasing the beta of the firms in our sa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.